BACKGROUND: "Frailty" is an adverse, primarily gerontologic, health condition regarded as frequent with aging and having severe consequences. Although clinicians claim that the extremes of frailty can be easily recognized, a standardized definition of frailty has proved elusive until recently. This article evaluates the cross-validity, criterion validity, and internal validity in the Women's Health and Aging Studies (WHAS) of a discrete measure of frailty recently validated in the Cardiovascular Health Study (CHS). METHODS: The frailty measure developed in CHS was delineated in the WHAS data sets. Using latent class analysis, we evaluated whether criteria composing the measure aggregate into a syndrome. We verified the criterion validity of the measure by testing whether participants defined as frail were more likely than others to develop adverse geriatric outcomes or to die. RESULTS: The distributions of frailty in the WHAS and CHS were comparable. In latent class analyses, the measures demonstrated strong internal validity vis à vis stated theory characterizing frailty as a medical syndrome. In proportional hazards models, frail women had a higher risk of developing activities of daily living (ADL) and/or instrumental ADL disability, institutionalization, and death, independently of multiple potentially confounding factors. CONCLUSIONS: The findings of this study are consistent with the widely held theory that conceptualizes frailty as a syndrome. The frailty definition developed in the CHS is applicable across diverse population samples and identifies a profile of high risk of multiple adverse outcomes.
BACKGROUND: "Frailty" is an adverse, primarily gerontologic, health condition regarded as frequent with aging and having severe consequences. Although clinicians claim that the extremes of frailty can be easily recognized, a standardized definition of frailty has proved elusive until recently. This article evaluates the cross-validity, criterion validity, and internal validity in the Women's Health and Aging Studies (WHAS) of a discrete measure of frailty recently validated in the Cardiovascular Health Study (CHS). METHODS: The frailty measure developed in CHS was delineated in the WHAS data sets. Using latent class analysis, we evaluated whether criteria composing the measure aggregate into a syndrome. We verified the criterion validity of the measure by testing whether participants defined as frail were more likely than others to develop adverse geriatric outcomes or to die. RESULTS: The distributions of frailty in the WHAS and CHS were comparable. In latent class analyses, the measures demonstrated strong internal validity vis à vis stated theory characterizing frailty as a medical syndrome. In proportional hazards models, frail women had a higher risk of developing activities of daily living (ADL) and/or instrumental ADL disability, institutionalization, and death, independently of multiple potentially confounding factors. CONCLUSIONS: The findings of this study are consistent with the widely held theory that conceptualizes frailty as a syndrome. The frailty definition developed in the CHS is applicable across diverse population samples and identifies a profile of high risk of multiple adverse outcomes.
Authors: Mara A McAdams-DeMarco; Andrew Law; Jingwen Tan; Cassandra Delp; Elizabeth A King; Babak Orandi; Megan Salter; Nada Alachkar; Niraj Desai; Morgan Grams; Jeremy Walston; Dorry L Segev Journal: Transplantation Date: 2015-04 Impact factor: 4.939
Authors: Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen Journal: Endocr Rev Date: 2012-03-20 Impact factor: 19.871
Authors: Nadia Sourial; Howard Bergman; Sathya Karunananthan; Christina Wolfson; Jack Guralnik; Hélène Payette; Luis Gutierrez-Robledo; Dorly J H Deeg; John D Fletcher; Maria T E Puts; Bin Zhu; François Béland Journal: J Gerontol A Biol Sci Med Sci Date: 2012-03-28 Impact factor: 6.053
Authors: Damani A Piggott; Ravi Varadhan; Shruti H Mehta; Todd T Brown; Huifen Li; Jeremy D Walston; Sean X Leng; Gregory D Kirk Journal: J Gerontol A Biol Sci Med Sci Date: 2015-09-18 Impact factor: 6.053
Authors: Claire Johnston; Sarah N Hilmer; Andrew J McLachlan; Slade T Matthews; Peter R Carroll; Carl M Kirkpatrick Journal: Eur J Clin Pharmacol Date: 2014-02-14 Impact factor: 2.953
Authors: Sameera A Talegawkar; Stefania Bandinelli; Karen Bandeen-Roche; Ping Chen; Yuri Milaneschi; Toshiko Tanaka; Richard D Semba; Jack M Guralnik; Luigi Ferrucci Journal: J Nutr Date: 2012-10-24 Impact factor: 4.798